9H-Purin-6-amine, 9-b-D-arabinofuranosyl-, hydrate(1:1) (CAS 24356-66-9) — formula C10H13N5O4, molecular weight 267.24; category organic chemicals.
| CAS Number | 24356-66-9 |
|---|---|
| Molecular Formula | C10H13N5O4 |
| Molecular Weight | 267.24 |
| Melting Point | 500 to 518 °F (NTP, 1992) |
| LogP | -2.115 |
| Applications | Uses: MEDICATION, THERAP CAT: ANTIVIRAL, A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus, VIRA-A Vidarabine, 3% ointment, ophthalmic: Discontinued, VIRA-A (vidarabine) eq 187.4 mg base, ml, injectable, injection: Discontinued, Used as an initial treatment for the termination of paroxysmal supraventricular tachycardia (PVST), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (SVT). Also used as an adjunct to thallous chloride TI 201 myocardial perfusion scintigraphy (thallium stress test) in patients who are unable to exercise adequately, as well as an adjunct to vagal maneuvers and clinical assessment to establish a specific diagnosis of undefined, stable, narrow-complex SVT., Methods of Manufacturing: Originally prepared by chemical synthesis at Stanford Research Institute, and later isolated from a fermentation beer of Streptomyces antibioticus., Formulations, Preparations: Ophthalmic Ointment 3% (equivalent to vidarabine, Vira-A, Parke-Davis anhydrous 2.8%), Parenteral: Concentrate, for injection, for iv infusion, 200 mg, ml (equivalent to 187.4 mg of anhydrous vidarabine per ml). Vira-A (with benzethonium chloride and phosphate buffers), Parke-Davis, Vidarabine, not currently approved for use in the United States, General Manufacturing Information: 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-: INACTIVE |
| Category | Organic Chemicals |
Documented applications: Uses: MEDICATION, THERAP CAT: ANTIVIRAL, A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus, VIRA-A Vidarabine, 3% ointment, ophthalmic: Discontinued, VIRA-A (vidarabine) eq 187.4 mg base, ml, injectable, injection: Discontinued, Used as an initial treatment for the termination of paroxysmal supraventricular tachycardia (PVST), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (SVT). Also used as an adjunct to thallous chloride TI 201 myocardial perfusion scintigraphy (thallium stress test) in patients who are unable to exercise adequately, as well as an adjunct to vagal maneuvers and clinical assessment to establish a specific diagnosis of undefined, stable, narrow-complex SVT., Methods of Manufacturing: Originally prepared by chemical synthesis at Stanford Research Institute, and later isolated from a fermentation beer of Streptomyces antibioticus., Formulations, Preparations: Ophthalmic Ointment 3% (equivalent to vidarabine, Vira-A, Parke-Davis anhydrous 2.8%), Parenteral: Concentrate, for injection, for iv infusion, 200 mg, ml (equivalent to 187.4 mg of anhydrous vidarabine per ml). Vira-A (with benzethonium chloride and phosphate buffers), Parke-Davis, Vidarabine, not currently approved for use in the United States, General Manufacturing Information: 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-: INACTIVE.
9H-Purin-6-amine, 9-b-D-arabinofuranosyl-, hydrate(1:1) is a carbon-based organic compound with CAS registry number 24356-66-9 and molecular formula C10H13N5O4 (molecular weight 267.24), belonging to the organic chemicals segment of chemical raw materials.
CAS number: 24356-66-9
Its molecular formula C10H13N5O4 comprises 10 C, 13 H, 5 N, 4 O atoms.
Also known as: 9H-Purin-6-amine, 9-b-D-arabinofuranosyl-, hydrate(1:1) · 9H-嘌呤-6-胺，9-b-D-阿拉伯呋喃糖基-，水合物(1:1)
Category: organic chemicals
The CAS registry number of 9H-Purin-6-amine, 9-b-D-arabinofuranosyl-, hydrate(1:1) is 24356-66-9.
Molecular formula C10H13N5O4, molecular weight 267.24.
It is also registered under: 9H-Purin-6-amine, 9-b-D-arabinofuranosyl-, hydrate(1:1), 9H-嘌呤-6-胺，9-b-D-阿拉伯呋喃糖基-，水合物(1:1).
Recorded applications: Uses: MEDICATION, THERAP CAT: ANTIVIRAL, A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus, VIRA-A Vidarabine, 3% ointment, ophthalmic: Discontinued, VIRA-A (vidarabine) eq 187.4 mg base, ml, injectable, injection: Discontinued, Used as an initial treatment for the termination of paroxysmal supraventricular tachycardia (PVST), including that associated with accessory bypass tracts, and is a drug of choice for terminating stable, narrow-complex supraventricular tachycardias (SVT). Also used as an adjunct to thallous chloride TI 201 myocardial perfusion scintigraphy (thallium stress test) in patients who are unable to exercise adequately, as well as an adjunct to vagal maneuvers and clinical assessment to establish a specific diagnosis of undefined, stable, narrow-complex SVT., Methods of Manufacturing: Originally prepared by chemical synthesis at Stanford Research Institute, and later isolated from a fermentation beer of Streptomyces antibioticus., Formulations, Preparations: Ophthalmic Ointment 3% (equivalent to vidarabine, Vira-A, Parke-Davis anhydrous 2.8%), Parenteral: Concentrate, for injection, for iv infusion, 200 mg, ml (equivalent to 187.4 mg of anhydrous vidarabine per ml). Vira-A (with benzethonium chloride and phosphate buffers), Parke-Davis, Vidarabine, not currently approved for use in the United States, General Manufacturing Information: 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-: INACTIVE.
Category: Organic Chemicals.
Independent reference data for 9H-Purin-6-amine, 9-b-D-arabinofuranosyl-, hydrate(1:1) (CAS 24356-66-9), compiled from public chemistry databases.
| CAS Registry Number | 24356-66-9 |
|---|---|
| PubChem CID | 21704 |
| Molecular formula | C10H13N5O4 |
| IUPAC name | (2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol |
| UNII (FDA) | 3XQD2MEW34 |
| Molecular Weight | 267.24 |
|---|---|
| XLogP3 | -1.1 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 2 |
| Exact Mass | 267.09675391 |
| Monoisotopic Mass | 267.09675391 |
| Topological Polar Surface Area | 140 |
| Heavy Atom Count | 19 |
| Melting Point | 500 to 518 °F (NTP, 1992) |
|---|---|
| Melting Point | 257.0-257.5 °C (0.4 H2O) |
| Melting Point | 257.00 °C. @ 760.00 mm Hg |
| Solubility | 1.40e+01 g/L |
| LogP | -2.115 |
| LogP | log Kow = -1.11 |
Vidarabine; 5536-17-4; Adenine arabinoside; Ara-A; Arabinosyladenine; Vira-A; Spongoadenosine; Araadenosine; Arasena-A; Vidarabin; 9-beta-D-Arabinofuranosyladenine; Vidarabine anhydrous; Vidarabina; Vidarabinum; beta-D-Arabinosyladenine; NSC-404241
| Reported hazard statements | H361 (97.6%) |
|---|
H361 (97.6%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
9H-Purin-6-amine, 9-b-D-arabinofuranosyl-, hydrate(1:1) · CAS 24356-66-9 · C10H13N5O4. UNII 3XQD2MEW34. Melting Point: 500 to 518 °F (NTP, 1992); Melting Point: 257.0-257.5 °C (0.4 H2O); Melting Point: 257.00 °C. @ 760.00 mm Hg.
Source: PubChem / Wikidata; the batch COA governs where values differ.
Supplier: Jinan Shenghe Chemical Co., Ltd.